PM
LKFT

Prosight Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Prosight Management’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.5M Buy
1,550,000
+475,888
+44% +$15.8M 7.63% 5
2025
Q4 		$35.1M Sell
1,074,112
-75,888
-7% -$2.45M 7.26% 2
2025
Q3 		$39.8M Sell
1,150,000
-623,649
-35% -$20M 9.29% 1
2025
Q2 		$49.6M Buy
1,773,649
+458,751
+35% +$12.3M 12.11% 1
2025
Q1 		$33M Buy
1,314,898
+289,898
+28% +$7.33M 10.85% 1
2024
Q4 		$28.2M Sell
1,025,000
-3,843
-0.4% -$107K 7.79% 1
2024
Q3 		$29.6M Sell
1,028,843
-321,137
-24% -$8.74M 7.29% 2
2024
Q2 		$33.5M Buy
1,349,980
+418,468
+45% +$11.9M 10% 1
2024
Q1 		$30M Buy
931,512
+104,218
+13% +$3.88M 8.34% 3
2023
Q4 		$33.6M Buy
827,294
+97,087
+13% +$3.57M 13.5% 1
2023
Q3 		$25.2M Buy
730,207
+312,707
+75% +$12.2M 8% 3
2023
Q2 		$17M Buy
417,500
+42,000
+11% +$1.71M 4.97% 7
2023
Q1 		$14.5M Sell
375,500
-89,500
-19% -$3.68M 6.88% 2
2022
Q4 		$20.6M Buy
465,000
+60,000
+15% +$2.52M 11.25% 1
2022
Q3 		$17.3M Buy
405,000
+36,000
+10% +$1.84M 9.25% 3
2022
Q2 		$20.6M Sell
369,000
-5,000
-1% -$296K 16.22% 1
2022
Q1 		$23.2M Buy
374,000
+28,100
+8% +$1.72M 14.98% 1
2021
Q4 		$19.1M Buy
345,900
+95,220
+38% +$4.97M 11.42% 2
2021
Q3 		$13.2M Buy
250,680
+178,680
+248% +$10.6M 7.26% 3
2021
Q2 		$4.96M Buy
72,000
+5,581
+8% +$426K 3.1% 13
2021
Q1 		$5.12M Buy
+66,419
New +$6.12M 4.19% 9
2019
Q1 		– Sell
-62,850
Closed -$5.77M – 41
2018
Q4 		$5.77M Buy
+62,850
New +$6.37M 2.98% 12

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DCM
DME Capital Management New York $3.19B AUM 23.22% 1-Year Est. Return
SBH
Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Prosight Management's LKFT Position: Q1 2026 in Review

Prosight Management increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 44% in Q1 2026, buying an estimated $15.8M and bringing the position to 1,550,000 shares worth $46.5M. The position accounts for 7.63% of the portfolio, ranked #5.

Prosight Management first reported a position in LKFT in Q4 2018 and has held it in 22 quarters since. The position peaked at $49.6M in Q2 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • Prosight Management held 1,550,000 shares of Lakefront Biotherapeutics American Depositary Shares worth $46.5M as of Q1 2026.
  • Prosight Management bought 475,888 Lakefront Biotherapeutics American Depositary Shares shares in Q1 2026, an estimated $15.8M.
  • Lakefront Biotherapeutics American Depositary Shares made up 7.63% of Prosight Management's portfolio in Q1 2026, its #5 holding.
  • Prosight Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2018 and has held it in 22 quarters since.
  • Prosight Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $49.6M in Q2 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.